STOCK TITAN

[6-K] YS Biopharma Co., Ltd. Warrants Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Ciena Corporation (CIEN) has filed a Form 144 indicating that an insider plans to sell 734 common shares through Morgan Stanley Smith Barney LLC on or about 15 July 2025 via the NYSE. The proposed transaction is valued at $60,606.38 and represents less than 0.001 % of CIEN’s 141,367,218 shares outstanding. The shares were acquired as restricted stock on 20 June 2025. No other insider sales were reported in the last three months, and the filing contains no additional financial or operational disclosures.

Ciena Corporation (CIEN) ha presentato un Modulo 144 che indica che un dirigente intende vendere 734 azioni ordinarie tramite Morgan Stanley Smith Barney LLC intorno al 15 luglio 2025 attraverso la NYSE. L'operazione proposta ha un valore di 60.606,38 $ e rappresenta meno dello 0,001 % delle 141.367.218 azioni in circolazione di CIEN. Le azioni sono state acquisite come azioni vincolate il 20 giugno 2025. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di dirigenti e il documento non contiene ulteriori informazioni finanziarie o operative.

Ciena Corporation (CIEN) ha presentado un Formulario 144 indicando que un insider planea vender 734 acciones comunes a través de Morgan Stanley Smith Barney LLC alrededor del 15 de julio de 2025 mediante la NYSE. La transacción propuesta está valorada en 60,606.38 $ y representa menos del 0.001 % de las 141,367,218 acciones en circulación de CIEN. Las acciones fueron adquiridas como acciones restringidas el 20 de junio de 2025. No se reportaron otras ventas de insiders en los últimos tres meses y la presentación no contiene divulgaciones financieras u operativas adicionales.

Ciena Corporation (CIEN)은 내부자가 2025년 7월 15일경 NYSE를 통해 Morgan Stanley Smith Barney LLC를 통해 734주의 보통주를 매도할 계획임을 알리는 Form 144를 제출했습니다. 제안된 거래 금액은 60,606.38달러이며 CIEN의 141,367,218주 발행 주식의 0.001 % 미만에 해당합니다. 해당 주식은 2025년 6월 20일 제한 주식으로 취득되었습니다. 최근 3개월간 다른 내부자 매도 보고는 없었으며, 제출서에는 추가적인 재무 또는 운영 공시가 포함되어 있지 않습니다.

Ciena Corporation (CIEN) a déposé un formulaire 144 indiquant qu’un initié prévoit de vendre 734 actions ordinaires via Morgan Stanley Smith Barney LLC aux alentours du 15 juillet 2025 par l’intermédiaire de la NYSE. La transaction proposée est évaluée à 60 606,38 $ et représente moins de 0,001 % des 141 367 218 actions en circulation de CIEN. Les actions ont été acquises en tant qu’actions restreintes le 20 juin 2025. Aucune autre vente d’initié n’a été signalée au cours des trois derniers mois et le dépôt ne contient pas d’autres divulgations financières ou opérationnelles.

Die Ciena Corporation (CIEN) hat ein Formular 144 eingereicht, das darauf hinweist, dass ein Insider plant, 734 Stammaktien über Morgan Stanley Smith Barney LLC etwa am 15. Juli 2025 über die NYSE zu verkaufen. Die vorgeschlagene Transaktion hat einen Wert von 60.606,38 $ und entspricht weniger als 0,001 % der 141.367.218 ausstehenden CIEN-Aktien. Die Aktien wurden am 20. Juni 2025 als eingeschränkte Aktien erworben. In den letzten drei Monaten wurden keine weiteren Insiderverkäufe gemeldet, und die Einreichung enthält keine zusätzlichen finanziellen oder operativen Angaben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Very small insider sale; governance disclosure routine and immaterial to valuation.

The Form 144 reflects a proposed sale of only 734 shares, worth roughly $60 k, vs. a share count exceeding 141 million. Such a fraction (<0.001 %) is statistically insignificant and does not alter ownership structure or signal strategic intent. Because the shares were recently granted as restricted stock, the filing appears to be a standard liquidity move rather than a directional view on CIEN’s prospects. No red-flags such as clustered selling, accelerated timing, or non-public information concerns are evident. I view the impact on investors as neutral.

TL;DR: Transaction is de minimis; should not influence portfolio positioning.

From a portfolio perspective, the dollar value and share count are trivial. Liquidity of CIEN averages well above 1 million shares daily, so the market can easily absorb 734 shares without price disruption. There are no accompanying operational metrics or guidance changes. Consequently, I classify this event as non-impactful and keep my investment thesis unchanged.

Ciena Corporation (CIEN) ha presentato un Modulo 144 che indica che un dirigente intende vendere 734 azioni ordinarie tramite Morgan Stanley Smith Barney LLC intorno al 15 luglio 2025 attraverso la NYSE. L'operazione proposta ha un valore di 60.606,38 $ e rappresenta meno dello 0,001 % delle 141.367.218 azioni in circolazione di CIEN. Le azioni sono state acquisite come azioni vincolate il 20 giugno 2025. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di dirigenti e il documento non contiene ulteriori informazioni finanziarie o operative.

Ciena Corporation (CIEN) ha presentado un Formulario 144 indicando que un insider planea vender 734 acciones comunes a través de Morgan Stanley Smith Barney LLC alrededor del 15 de julio de 2025 mediante la NYSE. La transacción propuesta está valorada en 60,606.38 $ y representa menos del 0.001 % de las 141,367,218 acciones en circulación de CIEN. Las acciones fueron adquiridas como acciones restringidas el 20 de junio de 2025. No se reportaron otras ventas de insiders en los últimos tres meses y la presentación no contiene divulgaciones financieras u operativas adicionales.

Ciena Corporation (CIEN)은 내부자가 2025년 7월 15일경 NYSE를 통해 Morgan Stanley Smith Barney LLC를 통해 734주의 보통주를 매도할 계획임을 알리는 Form 144를 제출했습니다. 제안된 거래 금액은 60,606.38달러이며 CIEN의 141,367,218주 발행 주식의 0.001 % 미만에 해당합니다. 해당 주식은 2025년 6월 20일 제한 주식으로 취득되었습니다. 최근 3개월간 다른 내부자 매도 보고는 없었으며, 제출서에는 추가적인 재무 또는 운영 공시가 포함되어 있지 않습니다.

Ciena Corporation (CIEN) a déposé un formulaire 144 indiquant qu’un initié prévoit de vendre 734 actions ordinaires via Morgan Stanley Smith Barney LLC aux alentours du 15 juillet 2025 par l’intermédiaire de la NYSE. La transaction proposée est évaluée à 60 606,38 $ et représente moins de 0,001 % des 141 367 218 actions en circulation de CIEN. Les actions ont été acquises en tant qu’actions restreintes le 20 juin 2025. Aucune autre vente d’initié n’a été signalée au cours des trois derniers mois et le dépôt ne contient pas d’autres divulgations financières ou opérationnelles.

Die Ciena Corporation (CIEN) hat ein Formular 144 eingereicht, das darauf hinweist, dass ein Insider plant, 734 Stammaktien über Morgan Stanley Smith Barney LLC etwa am 15. Juli 2025 über die NYSE zu verkaufen. Die vorgeschlagene Transaktion hat einen Wert von 60.606,38 $ und entspricht weniger als 0,001 % der 141.367.218 ausstehenden CIEN-Aktien. Die Aktien wurden am 20. Juni 2025 als eingeschränkte Aktien erworben. In den letzten drei Monaten wurden keine weiteren Insiderverkäufe gemeldet, und die Einreichung enthält keine zusätzlichen finanziellen oder operativen Angaben.

&nbsp;

&nbsp;

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

&nbsp;

&nbsp;

&nbsp;

FORM 6-K

&nbsp;

&nbsp;

&nbsp;

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

&nbsp;

For the month of July 2025

&nbsp;

Commission file number: 001-41598

&nbsp;

&nbsp;

&nbsp;

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

&nbsp;

&nbsp;

&nbsp;

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

&nbsp;

&nbsp;

&nbsp;

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

&nbsp;

Form 20-F &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F

&nbsp;

&nbsp;

&nbsp;

&nbsp;

&nbsp;

&nbsp;

LAKESHORE BIOPHARMA REPORTS CHANGE IN CONTROL

&nbsp;

On July 8, 2025, LakeShore Biopharma Co., Ltd (the &ldquo;Company&rdquo;) entered into a Share and Warrant Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with an investor, namely Crystal Peak Investment Inc. (&ldquo;Crystal Investment&rdquo;), relating to the offer and sale of 16,987,542 ordinary shares of the Company, par value US$0.0002 per share (&ldquo;Ordinary Shares&rdquo;), and warrants to purchase an additional 16,987,542 Ordinary Shares (the &ldquo;Warrants&rdquo;) for an aggregate purchase price of US$15 million in a private placement (the &ldquo;Private Placement&rdquo;). The closing of the Private Placement occurred on July 8, 2025. Subsequent to the closing, on July 11, 2025, the Company issued 4,033,790 Ordinary Shares to Crystal Investment in connection with its full exercise of the Warrants on a cashless basis.

&nbsp;

To the Company&rsquo;s knowledge, the number of Ordinary Shares beneficially owned by Crystal Investment is 21,021,332, representing approximately 51.0% of the 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025.

&nbsp;

INCORPORATION BY REFERENCE

&nbsp;

This current report on Form 6-K shall be deemed to be incorporated by reference into the Company&rsquo;s registration statements on Form S-8 (File No. 333-279544 and File No. 333-273165) and to be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

&nbsp;

1

&nbsp;

&nbsp;

Signature

&nbsp;

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

&nbsp;

&nbsp; LakeShore Biopharma Co., Ltd
&nbsp; &nbsp;
&nbsp; By: /s/ Rachel Yu
&nbsp; Name:&nbsp; Rachel Yu
&nbsp; Title: Director and Chief Financial Officer

&nbsp;

Date: July 15, 2025

&nbsp;

&nbsp;

2

&nbsp;

YS Biopharma Co., Ltd. Warrants

NASDAQ:YSBPW

YSBPW Rankings

YSBPW Latest News

YSBPW Latest SEC Filings

YSBPW Stock Data

93.06M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services